Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists

Details for Australian Patent Application No. 2005305086 (hide)

Owner Arena Pharmaceuticals, Inc.

Inventors Connolly, Daniel T.; Richman, Jeremy; Behan, Dominic P.

Agent FB Rice

Pub. Number AU-A-2005305086

PCT Pub. Number WO2006/052569

Priority 60/625,536 05.11.04 US

Filing date 1 November 2005

Wipo publication date 18 May 2006

International Classifications

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/416 (2006.01) - condensed with carbocyclic ring systems, e.g. indazole

A61K 31/4162 (2006.01) - condensed with heterocyclic ring systems

A61K 31/455 (2006.01) - Nicotinic acid, i.e. niacin

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

Event Publications

10 May 2007 PCT application entered the National Phase

  PCT publication WO2006/052569 Priority application(s): WO2006/052569

5 November 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005305088-Technique and instrumentation for measuring and preparing a vertebral body for device implantation using datum block

2005305083-GPR41 and modulators thereof for the treatment of insulin-related disorders